Watch the 22 sessions from SOSV Climate Tech Summit!

Prellis Biologics

Human tissue printing and pharmaceutical development

Team

Melanie Matheu

CEO & Founder

Kevin Chapman

CSO

Yelda Kaya

CBO

Company details

Prellis Biologics is 32 days from anti-COVID-19 human antibodies, using their bioprinted, human mini lymph nodes. In 2017, Prellis Biologics printed human mini lymph nodes, which they injected with Zika virus. The mini lymph nodes produced human antibodies for passive immunity against Zika. Now, Prellis is doing the same for the coronavirus. In one week, they will be growing immune cells, in two weeks growing lymph nodes, and in a month screening the antibodies. In six weeks the antibodies will be sequenced for scale-up and trials, which could begin in as soon as 10 weeks. This is a much faster turnaround time for antibodies and even if other approaches yield antibodies first, Prellis’ approach is a more rapid way to generate antibodies as the virus mutates.
Anti-COVID-19 Antibodies via 3D Printed Human Lymph Nodes
Primer on the the three major treatment strategies for defense against COVID-19
White Paper on Prellis-created antibody production
Deck on above strategy

Get In Touch with Prellis Biologics

Please tell us a little bit about yourself and why you'd like to get connected. Prellis Biologics + SOSV will follow up with you via email.

Hidden
Hidden
Hidden
Hidden
* If you are interested in investing directly into SOSV's portfolio of privately held companies, or into SOSV's funds, you need to meet the SEC’s criteria for accredited investor status. As an individual, you can qualify as an accredited investor by either (a) having more than $200,000 in annual income for each of the past two years (or $300,000 with your spouse) and a reasonable expectation of earning the same this year or (b) having a net worth of at least $1 million (not including your principal residence). Learn More

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.